Centenial Surgical Suture Intrinsic Value
Centenial Surgical Suture (CSURGSU) median intrinsic value is ₹160.00 from 4 valuation models (range ₹100–₹200), vs current price ₹80.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse CSURGSU shareholder distribution to track promoter, FII and institutional holdings.
CSURGSU Valuation Methods Summary — DCF, Graham Number & P/E
Centenial Surgical Suture intrinsic value across 4 models vs current price ₹80.00 — upside/downside and value range per method. Read CSURGSU dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹116.00 | ₹104.40 - ₹127.60 | +45.0% | Book Value/Share: ₹58.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹160.00 | ₹144.00 - ₹176.00 | +100.0% | Revenue/Share: ₹108.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹100.00 | ₹90.00 - ₹110.00 | +25.0% | EBITDA: ₹5.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹200.00 | ₹160.00 - ₹240.00 | +150.0% | CF Growth: 15.0%, Discount: 15% |
CSURGSU Intrinsic Value vs Market Price — All Valuation Models
Centenial Surgical Suture fair value range ₹100–₹200 vs current market price ₹80.00 across 4 valuation models. For current market price and key ratios, visit Centenial Surgical Suture stock price NSE.
CSURGSU Intrinsic Value Analysis — Undervalued or Overvalued?
Centenial Surgical Suture median intrinsic value ₹160.00, current price ₹80.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of CSURGSU?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Centenial Surgical Suture (CSURGSU) is ₹160.00 (median value). With the current market price of ₹80.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹100.00 to ₹200.00, indicating ₹100.00 - ₹200.00.
Is CSURGSU undervalued or overvalued?
Based on our multi-method analysis, Centenial Surgical Suture (CSURGSU) appears to be trading below calculated value by approximately 100.0%.
CSURGSU Financial Health — Key Ratios vs Industry Benchmarks
Centenial Surgical Suture financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -6.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
CSURGSU Cash Flow Quality — Operating & Free Cash Flow
Centenial Surgical Suture operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹17 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹6 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹5 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |